AxoGen, Inc. $AXGN Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. grew its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 41.9% during the first quarter, HoldingsChannel reports. The institutional investor owned 660,553 shares of the medical equipment provider’s stock after buying an additional 194,949 shares during the quarter. Bessemer Group Inc.’s holdings in AxoGen were worth $21,885,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. MCF Advisors LLC bought a new stake in shares of AxoGen in the 4th quarter valued at approximately $30,000. Arax Advisory Partners lifted its holdings in AxoGen by 362.4% in the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 819 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in AxoGen in the fourth quarter worth $36,000. Kestra Advisory Services LLC acquired a new position in shares of AxoGen during the fourth quarter valued at $39,000. Finally, Aquatic Capital Management LLC boosted its position in shares of AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 1,269 shares during the period. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Up 0.2%

Shares of AXGN stock opened at $39.85 on Friday. The stock has a 50 day moving average of $42.29 and a 200-day moving average of $36.80. The firm has a market cap of $2.12 billion, a PE ratio of -62.27 and a beta of 1.09. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. AxoGen, Inc. has a 12 month low of $11.25 and a 12 month high of $46.95.

AxoGen (NASDAQ:AXGN) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). The company had revenue of $61.46 million during the quarter, compared to the consensus estimate of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. On average, equities analysts predict that AxoGen, Inc. will post -0.37 EPS for the current year.

Insider Buying and Selling at AxoGen

In other news, Director Amy Mcbride Wendell sold 1,647 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $42.60, for a total transaction of $70,162.20. Following the sale, the director owned 93,826 shares in the company, valued at approximately $3,996,987.60. This represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Johnson sold 11,050 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $43.26, for a total transaction of $478,023.00. Following the completion of the sale, the director directly owned 11,050 shares of the company’s stock, valued at approximately $478,023. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 29,041 shares of company stock worth $1,268,792 over the last three months. Company insiders own 2.44% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research report on Friday, May 29th. Raymond James Financial reissued an “outperform” rating and issued a $48.00 price objective on shares of AxoGen in a research note on Wednesday, April 29th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Citizens Jmp raised their target price on AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company raised their target price on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, AxoGen has an average rating of “Moderate Buy” and an average target price of $46.50.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.